In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
OCRA Featured in Fortune on Surgery That Reduces Ovarian Cancer Risk
A Fortune article published on June 16, 2025, titled I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know … Continued
Ovarian Cancer Research Alliance Partners with Iris by OncoHealth to Expand Access to the Steps Counseling Program
New collaboration enhances support for gynecologic cancer patients through integrated digital and personalized care New York, NY — [June 11, 2025] — Ovarian Cancer Research Alliance (OCRA), the largest global organization … Continued
The Overview: May 2025
Global Collaborative Research Push Resonates Across Airwaves The launch of the Global Ovarian Cancer Research Consortium has garnered significant media attention, with coverage appearing on NBC News Radio, FOX 5 Washington D.C., KUNS-TV … Continued